Dilated cardiomyopathy and the dystrophin gene: an illustrated review

Anders Oldfors, Bengt O Eriksson, Mårten Kyllerman, Tommy Martinsson, Jan Wahlström

Abstract
Cardiomyopathy is often found in patients with Duchenne and Becker muscular dystrophy, which are X linked muscle diseases caused by mutations in the dystrophin gene. Dystrophin defects present in many different ways and cases of mild Becker muscular dystrophy have been described in which cardiomyopathy was severe. Female carriers of Duchenne muscular dystrophy can develop symptomatic skeletal myopathy alone or combined with dilated cardiomyopathy. They can also develop dilated cardiomyopathy alone. X linked dilated cardiomyopathy has been found in association with dystrophin defects. The relation between the molecular defects and the cardiac phenotypes has not yet been established. New mutations in the dystrophin gene are common and such mutations cause one third of the cases with Duchenne and Becker muscular dystrophy. This means that sporadic cases of cardiomyopathy caused by dystrophin defects are likely. This paper reports such a case in a boy of 14 who died of dilated cardiomyopathy. Before the cardiac investigation, which was performed one month before he died, he had not complained of muscular weakness. He had minor signs of limb girdle myopathy and slightly increased concentrations of serum creatine kinase. He was found to have an unusual deletion in the dystrophin gene.

(Dr Heart J 1994;72:344–348)

Duchenne and Becker muscular dystrophy
Duchenne muscular dystrophy is a X linked disease with onset in early childhood that causes severe muscle wasting and death before 25 years of age. The gene involved in Duchenne muscular dystrophy was identified in 1987 and the corresponding protein was named dystrophin.1-2 The gene is very large and includes more than 70 protein encoding regions (exons). Dystrophin in skeletal and cardiac muscle is a 427 kD protein with various functions. One major function that has been proposed is anchoring of the cytoskeletal protein actin to the dystrophin-associated glycoprotein complex in the plasma membrane of muscle cells.3 In Duchenne muscular dystrophy there is pronounced deficiency of dystrophin. This deficiency is usually caused by deletions or point mutations in the dystrophin gene which lead to a shift in the reading frame and produce a stop codon and deficient synthesis of dystrophin.4 Becker muscular dystrophy is a milder variant that is also caused by mutations in the dystrophin gene, usually deletions without shift in the reading frame. Patients usually can walk and have a normal life span. In some cases there are duplications of one or several exons. In Becker muscular dystrophy the amount of dystrophin is normal or near normal, but the protein is often smaller than normal and a segment corresponding to the deletion in the gene is missing.5 New techniques for investigating the dystrophin gene and gene product have shown that dystrophinopathy may be expressed clinically in many different ways—for example, as muscle cramps as the only symptom or high serum creatine kinase (s-CK) as the only evidence of muscle disease.6-9 Female carriers of the mutation usually are symptom free, but some have symptoms. In some cases this may be due to a non-random inactivation of the X chromosomes, leading to a predominant expression of the X chromosome that has a mutation in the dystrophin gene.10

Cardiomyopathy in Duchenne and Becker muscular dystrophy
Although muscle weakness is the presenting and predominant symptom in Duchenne muscular dystrophy, dilated cardiomyopathy is often seen and can be severe.11 Several cases of dilated cardiomyopathy have been described in patients with Becker muscular dystrophy12-16 and some patients have had cardiac transplantation.17,18 Dilated cardiomyopathy, which is rarely the presenting symptom in Becker muscular dystrophy, usually appears in adulthood. However, Yoshida et al recently described four patients with Becker muscular dystrophy and deletions in the dystrophin gene who presented with cardiomyopathy.18 Two of these had no or slight muscle weakness and fatal myocardial involvement had developed when they were teenagers. Both had a deletion in exon 1 in the dystrophin gene.

In theory female carriers of Duchenne and Becker muscular dystrophy can show dystrophin defects in 50% of the mononucleated myocardial cells because of random inactivation of either the normal or mutated X chromosome. This fact can be used to identify

Department of Pathology, Gothenburg University, Sahlgrens Hospital, Gothenburg, Sweden A Oldfors Department of Paediatrics, Gothenburg University, East Hospital, Gothenburg, Sweden B O Eriksson M Kyllerman Department of Clinical Genetics, East Hospital, Gothenburg, Sweden T Martinsson J Wahlström

Correspondence to: Dr Anders Oldfors, Department of Pathology, Sahlgren's Hospital, S-413 45 Göteborg, Sweden.

Accepted for publication 26 April 1994
female carriers by endomyocardial biopsy and immunostaining of the myocardium with antidi dystrophin antibodies. Female carriers of Duchenne and Becker muscular dystrophy often show clinical expression of myocardial involvement, and cardiomyopathy can be the only clinical manifestation.

**X linked dilated cardiomyopathy**

X linked cardiomyopathy is a rapidly progressive myocardial disorder presenting in teenage boys as a congestive heart failure without clinical signs of skeletal myopathy. Recently, X linked dilated cardiomyopathy in two pedigrees was shown to be linked to the Duchenne muscular dystrophy gene region (Xp21) and associated with a cardiac dystrophin defect in the amino-terminal region, but the mutation was not identified. There was an increase in muscle s-CK indicating skeletal muscle involvement. Muntoni et al described a deletion in the dystrophin muscle promoter region and exon 1 in one pedigree with X linked dilated cardiomyopathy. All affected boys showed an increase in muscle s-CK, and muscle biopsy, which was performed in one case, showed mild myopathic changes. The reason why some patients with dystrophinopathy present with severe cardiomyopathy despite mild skeletal myopathy is not clear. This may partly be because dystrophin has different functions in skeletal and cardiac muscle. The presence of an additional C-terminal transcript of dystrophin in cardiac muscle that is not present in skeletal muscle further complicates the picture. Further studies including clinical and molecular investigations of cardiac tissue from patients with cardiomyopathy caused by defective dystrophin are needed to establish the relation between the genotype and the cardiac phenotype.

A third of cases of Duchenne and Becker muscular dystrophies arise from new mutations, and a similar proportion of cases of dystrophinopathy with other clinical manifestations may also be caused by new mutations. The possibility that sporadic cases of idiopathic dilated cardiomyopathy may be caused by dystrophin defects prompted a recent study on a large series of patients with dilated cardiomyopathy; no dystrophin gene defects were confirmed in any of these cases, however the muscle promoter region was not investigated and the patients were adults. As in X linked dilated cardiomyopathy, it may be that sporadic cases of cardiomyopathy as the only clinical manifestation of a dystrophin defect will be found mainly among young people especially if there is an increase in s-CK.

**Report of a case**

We describe a boy of 14 who died of dilated cardiomyopathy. Before the cardiac investigation, which was performed one month before he died, he had not complained of muscular weakness. He was found to have an unusual deletion in the dystrophin gene.

This boy was the second child of unrelated healthy parents. A younger sister had died in infancy of volvulus of the small intestine. An older brother, now 25 years of age, has no signs of cardiac or skeletal muscle disease and normal s-CK. Their mother has no signs of muscle disease and her s-CK is normal. There is no family history of cardiac or skeletal muscle disease.

The patient was referred for cardiac investigation in 1987 because of congestive heart failure with a two month history of weight loss, increasing fatigue, and periods of abdominal pain and vomiting after upper respiratory tract infections. On admission he showed signs of heart dysfunction with gallop rhythm, left ventricular hypertrophy, low blood pressure (80/60 mm Hg), and severe heart enlargement on x ray. Electrocardiography showed tachycardia, left atrial and ventricular hypertrophy, and strain. Echocardiography showed considerable dilatation of the left ventricle (diastolic diameter 82 mm) and a fractional shortening of...
men obtained in 1987. Immunohistochemical analysis of dystrophin was performed on cryo-

tat sections with monoclonal anti-dystrophin antibodies (DYS 1, DYS 2, and DYS 3, Novocastra Laboratories, UK). The DYS 1 antibody recognises an epitope between amino acids 1181 and 1388 (exons 26 to 30 approximately), the DYS 2 antibody reacts with the last 17 amino acids of the carboxy terminal of dystrophin, and the DYS 3 antibody detects sequences between amino acids 308 and 351, spanning the junction of exons 9 and 10. The immunoreactive material was visualised by the avidin-biotin complex (ABC)-peroxidase method with diaminoben-

zidine as chromogen. We performed Western blot analysis using the DYS 1 monoclonal antibody. For molecular genetic analysis DNA was extracted from muscle tissue (the patient) or blood (the mother and brother). We used multiplex polymerase reaction (PCR) analysis to detect the presence or absence of 18 different deletion-prone regions of the dystrophin gene. We used three dif-

erent primer pairs to analyse dinucleotide repeats in the DMD gene region.

Immunohistochemical staining showed normal or slightly reduced immunoreactivity with the antibodies DYS 1 and DYS 2 and no immunoreactivity with antibody DYS 3 (fig 2). The PCR reaction did not amplify exons 6, 8, 12, and 13. The other 14 investigated segments of the dystrophin gene were ampli-

fied in a normal way, indicating a deletion from exon 6 to exon 13 that did not involve exon 4 and exon 17 (fig 2). Western blot analysis with the antibody DYS 1 showed a dystrophin protein of reduced size (fig 3). These results show that a deletion in the dys-


trophin gene of the patient had shortened the dystrophin protein by removing a segment near the amino terminal region. The analysis of dinucleotide repeats showed that the patient and his healthy brother had received different haplotypes from their mother in the

11%. There was also considerable left atrial dilatation with a left atrial to aortic diameter ratio of 1.78 and a left atrial diameter of 41 mm. The mixed venous oxygen saturation was only 42–52% indicating a very low card-

iac output. Selective angiography excluded coronary artery abnormalities. An endomy-

ocardial biopsy specimen was taken from the right ventricle and showed non-specific changes with interstitial fibrosis compatible with dilated cardiomyopathy (fig 1A).

Further clinical investigation showed mild generalised muscle weakness and slight mus-

cular atrophy with a limb girdle distribution. In several samples, the concentration of s-CK was slightly raised (5–15 μkat/l (normal <3.3

μkat/l)). Electromyography of the tibialis ante-

rior, rectus femoris, and biceps brachii mus-

cles was normal, whereas a biopsy specimen of skeletal muscle showed mild myopathic changes (fig 1B).

He was treated with digoxin, frusemide, and metoprolol. A cardiac transplantation was planned but the patient died one month later of congestive heart failure. A post-mortem examination was not performed.

The new knowledge of dystrophin prompted us to re-examine the muscle speci-

Figure 2 Results of the PCR and immuno-

histochemical investigation showing that the
deletion in the dystrophin gene corresponds to the region of the epitope of the DYS 3
antibody, which shows no immunoreactivity in the patient. The upper part of the figure shows the dystrophin gene. The exons investigated by PCR reaction are indicated by
arrows. P, muscle promoter. The deleted exons are indicated by solid bars. The hatched bars corre-
spond to the exons, that are most likely to be deleted. The middle part of the figure shows the dystrophin molecule and the epitopes of the three monoclonal antibodies. The photographs illustrate the immunohistochemical staining of dystrophin in the patient (upper row) and a control (lower row) with the three antibodies.

Figure 3 Result of Western blot analysis (upper lanes). The arrowed lane corresponds to the patient and shows the presence of dystrophin, which is smaller than in the controls (C). The intensity of the immunostaining is reduced because of the small amount of tissue available for analysis and is proportional to the reduced staining of the myosin band after staining with Coomassie blue (lower lanes).
Dilated cardiomyopathy and the dystrophin gene: an illustrated review

dystrophin gene. Therefore we could not unequivocally determine whether she is a carrier of the mutation.

Comments

Our patient had slight skeletal muscle involvement as judged by the small increase in s-CK and the minor muscle weakness; however, cardiac failure caused by dilated cardiomyopathy was severe. In this respect our case shows many features in common with patients in the recently described pedigrees with X-linked dilated cardiomyopathy associated with dystrophin defects7,8 caused by different mutations. Theoretically the deletion in our patient did not cause a shift in the reading frame; this accords with the presence of a truncated protein on the Western blot. Exons 9 and 10 are only rarely involved in deletions without a frame shift.9,37,38 This part of dystrophin may be a hinge region joining the amino terminal domain to the central rod domain, and may thus be of great importance to the conformation of dystrophin.39 This region may be more important in cardiac muscle than in skeletal muscle,9 since our patient had severe cardiac disease and mild skeletal myopathy. Or perhaps the amount of dystrophin was more severely reduced in the myocardium than in skeletal muscle. We did not have the opportunity to investigate dystrophin in the myocardium. The amount of dystrophin is important to the clinical expression. Beggs et al described a 7 year old boy with skeletal myopathy and an in-frame deletion of exons 6–13, but unlike our case this patient had very little dystrophin in skeletal muscle.4

Though we could not unequivocally determine whether the mother of our patient is a carrier of the mutation, this case emphasises the importance of investigating the gene and gene expression of dystrophin not only in cases of muscular dystrophy and X linked dilated cardiomyopathy but also in sporadic cases of dilated cardiomyopathy, especially in young individuals with raised s-CK, because the results may have important implications for genetic counselling.

The study was supported by grants from the Swedish Medical Research Council (Proj no 7122, and 3921). We thank Dr Bjorn Westrup, Falun, Sweden, for his cooperation.